SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending as investors debate the impact of ongoing monthly burn programs and upcoming community-led project launches on the chain's potential recovery. Market sentiment remains polarized, with many users focused on long-term accumulation and the prospects of a future supply shock, while others remain skeptical about the asset's utility and history.

Chip

Chip is experiencing high volatility following its simultaneous listing on major trading platforms, sparking a fierce debate within the community regarding its long-term potential as an AI infrastructure token versus its risk as a potential pump-and-dump scheme. Investors are actively discussing the token's circulating supply, its connection to GPU-backed lending, and the aggressive short-selling activity that has emerged alongside its recent price swings.

The Aircoin memecoin was born from a viral Twitter post from March, 2014 which proclaimed the following:   Evolution: 1. Aircoin 2. Fartcoin 3. Artcoin  Aircoin was launched in August, 2025 and CTO'd twice, with the second CTO team bringing vast experience and expertise to the project. The team includes industry veterans and visual arts professionals.  Aircoin is destined for greatness as a premier memecoin on the BONK.fun platform.

aircoin

Aircoin is gaining significant community traction as a long-term conviction play on Solana, driven by its unique 'AirLock' supply-locking mechanism and a focus on building sustainable value rather than relying on temporary hype. Investors are actively discussing the project's deep lore, transparent leadership, and high holder retention, positioning it as a resilient, community-owned alternative to shorter-lived meme narratives.

"What's Updog?" is a Community Led token.

UpDog

UpDog is gaining traction as a long-standing Solana-based project, driven by a dedicated community actively sharing dad jokes and promoting organic growth. Supporters are highlighting the project's multi-year history and its listing on decentralized exchange strict lists as key reasons for their continued commitment.

Dumb SEND IT

The $DSIT community is rallying around a "Dumb SEND IT" philosophy to drive momentum, with the developer actively engaging supporters through coin airdrops and community building as they push toward key market cap milestones. Investors are closely monitoring the project's growth, with many discussing the potential for a weekend rally as the community looks to increase its social media presence and secure upcoming chart integrations.

Lido DAO

Lido DAO is currently a focal point for community discussion as traders debate the protocol's long-term utility in the competitive liquid staking landscape. While some investors view the asset as a undervalued beta play on Ethereum, others remain cautious due to concerns over regulatory pressures, centralization risks, and ongoing whale selling activity.

Airgain, Inc. provides embedded antenna products, integration support and test services. The firm works in partnership with the entire ecosystem, including carriers, chipset suppliers, OEMs, and ODMs. Its products include embedded, external and carrier-class antennas. The company offers custom antenna design and performance validation services. Its antennas are deployed in carrier, fleet, enterprise, residential, private, government, and public safety wireless networks and systems, including set-top boxes, access points, routers, modems, gateways, media adapters, and asset tracking devices. The company was founded on March 20,1995 and is headquartered in San Diego, CA.

Airgain Inc

Airgain Inc is trending following news of a multi-million dollar design win with a major U.S. utility to deploy its wireless connectivity technology across its fleet. Investors are actively discussing the potential impact of this contract and whether the company can maintain this momentum to drive long-term revenue growth.

Silicon Motion Technology Corp. engages in the development, manufacture, and supply of semiconductor products for the electronics market. Its products include Flash Controllers, Storage Solutions, and others. It offers embedded and expandable storage, radio frequency integrated circuits and embedded graphics. The company was founded in November 1995 and is headquartered in Hong Kong.

Silicon Motion Technology Corp - ADR

Silicon Motion Technology Corp.

Silicon Motion is seeing significant volatility and investor interest following news that Chinese regulators have conditionally cleared its long-standing merger deal with MaxLinear. The community is actively debating the implications of the acquisition's path forward, with traders closely monitoring the spread between the current price and the deal's implied value as they navigate heightened volume and regulatory uncertainty.

GLOBALFOUNDRIES, Inc. provides foundry services and manufactures semiconductors. It offers global shuttle, mask, post-fab and turnkey services. The company was founded on October 7, 2008 and is headquartered in Malta, NY.

GlobalFoundries Inc

GlobalFoundries is currently drawing investor attention due to its strategic role as a domestic foundry player, benefiting from U.S. CHIPS Act funding and increasing interest in onshored semiconductor manufacturing for AI, defense, and power systems. Community sentiment highlights it as a critical 'picks and shovels' enabler that remains under-owned compared to high-profile AI stocks, with ongoing discussions focusing on the potential for long-term supply chain resilience and its positioning within the evolving semiconductor ecosystem.

Mobileye Global, Inc. engages in the business of developing and deploying driver assistance systems and autonomous driving technologies and solutions. It operates under the Mobileye and Other segments. The company was founded by Amnon Shashua and Ziv Aviram in 1999 and is headquartered in Jerusalem, Israel.

Mobileye Global Inc - Ordinary Shares - Class A

MOBILEYE GLOBAL INC

Mobileye Global is trending as investors weigh strong Q1 earnings growth and a new buyback program against ongoing volatility and bearish short interest. The community is actively debating the stock's potential for a short squeeze alongside its long-term strategic pivot toward robotaxis and physical AI.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Candel Therapeutics Stock Soars After Cantor Fitzgerald's Overweight Rating

Candel Therapeutics ripped higher on Monday after a bullish analyst initiation, underscoring how narrative can outpace fundamentals.read more...

Candel Therapeutics (NASDAQ:CADL) Sees Large Volume Increase - Time to Buy?

Candel Therapeutics (NASDAQ:CADL) Sees Unusually-High Trading Volume - Should You Buy...

<ul class="summary-bullets"><li>The firm stated that the stock is deeply undervalued, with a discounted cash flow estimate of around $30 per share.</li><li>Investors are awaiting extended phase 3 data for CAN-2409 in prostate cancer, as well as from the late-stage trial in non-small cell lung cancer.</li><li>Last month, Candel reported encouraging results from a phase 2a clinical trial of CAN-2409 in non-small cell lung cancer.</li></ul>Shares of Candel Therapeutics (CADL) drew strong retail interest on Monday after a bullish brokerage call labeled the stock “significantly undervalued,” with optimism building ahead of key trial data in lung and prostate cancer.Cantor Fitzgerald initiated coverage of Candel Therapeutics with an “Overweight” rating, according to The Fly. The brokerage expressed strong confidence in the stock’s outlook, stating that the shares are “deeply undervalued”, pointing to a discounted cash flow (DCF) estimate of around $30 per share and peak sales potential of $2.4 billion in prostate cancer.This represents a potential 370% upside from the stock’s Friday closing price of $6.37, when the stock recorded its highest intraday gains in more than 16 months. <a href="https://stocktwits.com/symbol/CADL">CADL shares</a> traded 0.5% lower in Monday’s pre-market.Cantor said the bullish view is backed by positive Phase 3 data, clear regulatory progress under a Special Protocol Agreement, limited competition, and a manageable safety profile. Additional upside could come from the company’s lung cancer program, which is advancing into late-stage trials.<h2 class="st-heading-2">CAN-2409 Shows Promise</h2>Last month, Candel Therapeutics reported encouraging results from a phase 2a clinical trial of CAN-2409 in non-small cell lung cancer. After an additional year of follow-up, 50% of patients were still alive at two years, despite a poor response to prior treatments, the firm said.The therapy also showed improved survival compared with standard care and remained well-tolerated. Researchers found it helped activate the immune system and turn previously unresponsive tumors into ones that could respond to treatment.Extended phase 3 results for CAN-2409 in prostate cancer are <a href="https://stocktwits.com/news-articles/markets/equity/cadl-stock-on-track-for-best-day-in-nearly-16-months-whats-driving-the-rally/cZJyGq6RIUn">expected</a> at the American Urological Association 2026 meeting in May. Investors in Candel Therapeutics are waiting for updates on its late-stage trial in non-small cell lung cancer and on other programs such as CAN-3110.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment on Stocktwits turned ‘extremely bullish’ from ‘bullish’ a day earlier. Message volume on the platform surged by around 70% over a 24-hour period, according to Stocktwits data.One user said the current share price offers a “tremendous opportunity.”<stembedurl>https://stocktwits.com/drizz/message/650754597</stembedurl>Year-to-date, the stock has gained around 7%.Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/cryptocurrency/btc-price-dropping-another-3-000-could-wipe-out-all-ceasefire-gains/cZBdJ8WRIyt">BTC Price Dropping Another $3,000 Could Wipe Out All Ceasefire Gains, Analyst Warns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CADL Stock Gets A Bullish Call Just Weeks Before Crucial Prostate Cancer Data Reveal

Cantor Fitzgerald initiated coverage of Candel Therapeutics with an “Overweight” rating, according to The Fly.

CADL Stock Posted Its Best Day In Nearly 16 Months On Friday – Why Does Cantor See A Further 370% Upside?

Equity

<ul class="summary-bullets"><li>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma featured in Parade magazine.</li><li>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma.</li><li>New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.</li></ul>Shares of Candel Therapeutics (CADL) jumped 24% on Friday as investors await upcoming clinical data readouts and process positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.The stock is now on track to record its best day since December 2024, if gains hold.<h2 class="st-heading-2">Positive Media Coverage</h2>In a post on X on Friday, Paul Peter Tak, chief executive officer of Candel Therapeutics, highlighted the story of Kyle Donahue, a five-year survivor of recurrent glioblastoma, featured in Parade magazine.Donahue, who was initially given only months to live after her diagnosis, participated in a clinical trial of the company’s investigational viral immunotherapy CAN-3110. Tak described the case as both deeply personal and scientifically meaningful, noting that such outcomes underscore the potential of viral immunotherapies to reshape the tumor microenvironment, activate durable immune responses, and represent a possible turning point in a disease where progress has long been elusive.<h2 class="st-heading-2">Upcoming Catalysts</h2>Candel investors are now awaiting further updates on the company’s planned late-stage trial in non-small cell lung cancer and other programs including CAN-3110 for glioblastoma. New data from the randomized late-stage trial of CAN-2409 in localized prostate cancer is scheduled for presentation at the American Urological Association (AUA) 2026 meeting in May.To add to the momentum, last month, the company announced positive updates for its lead candidate CAN-2409 in patients with advanced non-small cell lung cancer. The company said that extended long-term survival was observed after an additional year of follow-up in an ongoing phase 2a clinical trial, with 50% of 46 patients treated with CAN-2409 surviving beyond 24 months.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around CADL stock jumped from ‘neutral’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘extremely high’ levels.A few Stocktwits users expressed optimism for an upcoming buyout or partnership for the company.<stembedurl>https://www.stocktwits.com/drizz/message/650628803</stembedurl><stembedurl>https://www.stocktwits.com/gusm17/message/650618195</stembedurl>Another highlighted the positive press published on Parade, terming it “incredibly positive.”<stembedurl>https://www.stocktwits.com/pyroclast/message/650627286</stembedurl><a href="https://stocktwits.com/symbol/CADL">CADL stock</a> has gained 40% over the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/omer-stock-on-track-for-best-week-in-nearly-four-months-after-receiving-permanent-reimbursement-code-for-treatment/cZJUzYKRIUj">OMER Stock On Track For Best Week In Nearly 4 Months After Receiving Permanent Reimbursement Code For Treatment</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

CADL Stock On Track For Best Day In Nearly 16 Months — What’s Driving The Rally?

Candel stock is rallying on the heels of positive media coverage of a recurrent glioblastoma patient who took part in one of the company’s clinical trials.  

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Average Rating of "Hold" by Brokerages

Shares of Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) have earned a consensus recommendation of "Hold" from the eight analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and...

Candel Therapeutics (NASDAQ:CADL) Downgraded by Zacks Research to Strong Sell

Zacks Research downgraded Candel Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Tuesday...

Candel Therapeutics, Inc. (NASDAQ:CADL) Given Consensus Rating of "Moderate Buy" by Analysts

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the nine brokerages that are currently covering the company, MarketBeat...

FY2030 Earnings Forecast for CADL Issued By HC Wainwright

Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share estimates for shares of Candel Therapeutics in a research note issued to...

Short Interest in Candel Therapeutics, Inc. (NASDAQ:CADL) Grows By 39.7%

Candel Therapeutics, Inc. (NASDAQ:CADL - Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 27th, there was short interest totaling...

Portolan Capital Management LLC Trims Position in Candel Therapeutics, Inc. $CADL

Portolan Capital Management LLC trimmed its position in Candel Therapeutics, Inc. (NASDAQ:CADL - Free Report) by 14.7% during the third quarter, according to the company in its most recent Form 13F...

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q1 '26	-$0.30	--	--	N/A
Q4 '25	-$0.24	-$0.54	-120.94%	MISSED
Q3 '25	-$0.19	-$0.21	-13.40%	MISSED
Q2 '25	-$0.16	-$0.09	45.02%	BEAT
Q1 '25	-$0.37	$0.13	134.70%	BEAT

CADL
Candel Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q1 '26

Historical Earnings

Latest CADL News

CADLCandel Therapeutics Inc